Readers and Tweeters Sound Alarm Over Nurse’s Homicide Trial
KHN gives readers a chance to comment on a recent batch of stories.
Drugs
381 - 400 of 1,288 Results
-
-
KHN鈥檚 鈥榃hat the Health?鈥: News You Might Have Missed
Congress is in recess, so the slower-than-average news week gives us a chance to catch up on underreported topics, like Medicare鈥檚 coverage decision for the controversial Alzheimer鈥檚 disease drug Aduhelm and ominous new statistics on drug overdose deaths and sexually transmitted diseases. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, and Alice Miranda Ollstein of Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
A Travel Nurse Leaves Fears of Hospital Drug Tampering Across Three States
Kentucky nurse Jacqueline Brewster is accused of tampering with opioids in Tennessee and West Virginia, possibly contaminating drugs given to hospital patients.
By Brett Kelman -
Journalists Discuss Insulin Costs and Ethical Questions Surrounding a North Carolina Rehab Program
KHN staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
California Handed Its Medicaid Drug Program to One Company. Then Came a Corporate Takeover.
The company awarded the state鈥檚 Medi-Cal Rx contract was taken over by another company, Centene. That left the state with a contractor it didn鈥檛 pick 鈥 one that has been accused of overbilling nine other state Medicaid programs and is now under investigation by California.
-
KHN鈥檚 鈥榃hat the Health?鈥: Finally, a Fix for the 鈥楩amily Glitch鈥
President Joe Biden welcomed former President Barack Obama back to the White House this week to announce a new policy for the Affordable Care Act that would make subsidies available to more families with unaffordable employer coverage. Meanwhile, Congress struggled to find a compromise for continued federal funding of covid-19 vaccines, testing, and treatments. Tami Luhby of CNN, Shefali Luthra of The 19th, and Jessie Hellmann of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more.
-
Despite Doctors鈥 Concerns, Pharmacists Get More Leeway to Offer Treatment With Testing
In the battle against covid, pharmacies became a key place for consumers to seek vaccines and testing. Some states are expanding pharmacists鈥 work to include directly prescribing drugs for customers who seek some routine, point-of-care tests, such as those for flu or strep throat. But doctor groups oppose the move.
-
At a Tennessee Crossroads, Two Pharmacies, a Monkey, and Millions of Pills
Prosecutors say opioid-seeking patients drove hours to get their prescriptions filled in Celina, Tennessee, where pharmacies ignored signs of substance misuse and paid cash 鈥 or 鈥渕onkey bucks鈥 鈥 to keep customers coming back.
By Brett Kelman -
Big Pharma Is Betting on Bigger Political Ambitions From Sen. Tim Scott
The South Carolina senator led the congressional pack in pharma campaign contributions for the second half of 2021. There are clear reasons.
By Rachana Pradhan and Victoria Knight -
Campaign Contributions Tracker
Pharma Cash to Congress
A 麻豆女优 Health News database tracks campaign donations from drugmakers over the past 10 years.
-
Pfizer CEO Pushes Yearly Shots for Covid. Not So Fast, Experts Say.
A corporate CEO鈥檚 call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.
By Arthur Allen -
Covid鈥檚 鈥楽ilver Lining鈥: Research Breakthroughs for Chronic Disease, Cancer, and the Common Flu
Billions of dollars invested in mRNA vaccines and covid research could yield health care dividends for decades to come.
By Liz Szabo -
Letters to the Editor
Readers and Tweeters Remain Vigilant on Masking and Billing
KHN gives readers a chance to comment on a recent batch of stories.
By Terry Byrne -
鈥楢n Arm and a Leg鈥: Need an Expensive Drug? Here’s What You Need to Know
Even a personal finance expert can get stuck with a huge unexpected bill for a drug. Listen up for what you need to know about "copay accumulators."
-
Which Companies Aren鈥檛 Exiting Russia? Big Pharma
U.S. and global drug manufacturers invested in Russia鈥檚 sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
By Sarah Varney -
Patients Divided Over Alzheimer鈥檚 Drug: Is It a 鈥楻isk I鈥檓 Willing to Take鈥 or Just a 鈥楳agic Pill鈥?
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer鈥檚 disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
-
$35 Insulin Cap Is Welcome, Popular, and Bipartisan. But Congress May Not Pass It Anyway.
Spun off from the ailing but not-quite-dead Build Back Better legislation, a popular proposal to cap out-of-pocket insulin costs at $35 a month faces tough political realities that could kill it.
-
California Governor’s Big Promises on Drug Prices Are Slow to Materialize
Gov. Gavin Newsom has launched several initiatives to cut rising drug prices, but the savings haven鈥檛 been as monumental as he promised. And his plan to have California make its own generic drugs hasn鈥檛 gotten off the ground.
-
HIV Preventive Care Is Supposed to Be Free in the US. So, Why Are Some Patients Still Paying?
The Department of Labor issued rules in July clarifying that health plans need to cover the costs of prescription drugs proven to prevent HIV infection, along with related lab tests and medical appointments, at no cost to patients. More than half a year later, the erroneous billing continues.
By Sarah Varney -
Fact Check: Biden Sets High Bar in 1st State of the Union Speech
What a difference a year makes. The speech was delivered to a largely unmasked crowd of lawmakers, justices, and Cabinet members in the House chamber.
By Victoria Knight and Colleen DeGuzman